DreaMed Diabetes, a Tel Aviv, Israel-based startup specializing in AI-driven diabetes care solutions, has raised $3 million in a funding round.
Investors
The round was led by eHealth Ventures, a VC fund in Israel focused on finding, funding, and growing promising early-stage Israeli digital health companies. Their investments span from pre-seed to early-stage/pre-revenue ventures and can include non-dilutive equity funding.
DreaMed Diabetes Use of Funds
The company will use the funds to expand operations in the U.S., advance its platform, and grow the team. The funds will support scaling efforts, enhance technology, and drive new partnerships, including recent agreements with Abbott and Yale New Haven Health.
About DreaMed Diabetes
Established by Prof. Moshe Philip, Eran Atlas, Prof. Revital Nimri, and Ido Muller, DreaMed Diabetes is an innovative Israeli startup specializing in AI-driven solutions for diabetes care and management. Founded in 2014, the company focuses on developing advanced technology to improve insulin treatment for people with diabetes. Its flagship product, the endo.digital platform uses artificial intelligence to provide personalized recommendations for insulin treatment, helping healthcare providers optimize care and manage diabetes more effectively.
Funding Details
Company: DreaMed Diabetes
Raised: $3.0M
Round: Unknown
Funding Date: August 2024
Lead Investor: eHealth Ventures
Additional Investors:
Company Website: https://dreamed.ai/
Source: AI Diabetes Care and Management
Source: https://www.calcalistech.com/ctechnews/article/bjavutgsr